文献速递白血病

基于外周血原始细胞清除率优化去甲氧柔红霉素和阿糖胞苷诱导方案联合高三尖杉酯碱治疗新诊断急性髓系白血病:单臂2期试验

Optimization of idarubicin and cytarabine induction regimen with homoharringtonine for newly diagnosed acute myeloid leukemia patients based on the peripheral blast clearance rate: A single-arm, phase 2 trial (RJ-AML 2014).
PubMed 文献 · Am J Hematol · 2021-11-01

该单臂2期试验纳入151例新诊断AML患者,根据第5天外周血原始细胞清除率(D5-PBCR)对阳性患者早期加用高三尖杉酯碱(HHT)。首疗程总完全缓解率84.4%,D5-PBCR阴性组87.5%,阳性组80.0%;中位随访53.1个月,中位OS未达到,中位EFS为42.2个月,两组OS和EFS无显著差异;

要点

  • D5-PBCR阳性患者早期加用HHT后,首疗程完全缓解率达80.0%。
  • 加用HHT后3/4级不良事件发生率与未加用组相当。

核心结论

  • 根据D5-PBCR优化去甲氧柔红霉素和阿糖胞苷诱导方案在新诊断AML中可行。
  • 加用HHT显示出良好的疗效和安全性。

研究设计与样本

  • 单臂2期试验,纳入151例新诊断AML患者。
  • 65例为D5-PBCR阳性,其中55例完成含HHT的诱导治疗。
  • 主要终点为完全缓解(CR)。

主要发现

  • 首疗程总CR率为84.4%,D5-PBCR阴性组为87.5%,阳性组为80.0%。
  • 两组3/4级不良事件发生率相当。
  • 中位随访53.1个月,全队列中位OS未达到,中位EFS为42.2个月。
  • D5-PBCR阴性组与阳性组之间OS和EFS均无显著差异。

临床怎么用

  • 可根据D5-PBCR在诱导早期识别高危患者并加用HHT优化治疗。

局限性

  • 单臂设计,与历史数据比较而非随机对照。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Individualized chemotherapy, which is at the forefront of acute myeloid leukemia (AML) treatment, has moderately improved outcomes over the past decade. Monitoring the peripheral blood blast burden during induction by flow cytometry has shown significant value in the evaluation of treatment responses. Our previous study reported the day 5 peripheral blast clearance rate (D5-PBCR) as an indicator of early treatment response, and D5-PBCR (+) patients showed poor outcomes. We performed the present phase 2 trial of early intervention in D5-PBCR (+) patients with homoharringtonine (HHT) introduced in the traditional induction regimen with anthracycline and cytarabine. The primary endpoint was complete remission (CR). This study enrolled 151 patients, 65 patients were D5-PBCR (+) and 55 patients completed induction with HHT addition. The overall CR rate after one course of induction was 84.4%, with 87.5% and 80.0% for the D5-PBCR (-) and D5-PBCR (+) groups, respectively. The incidence of grade 3/4 adverse events was comparable between the two groups. At the median follow-up of 53.1 months, median overall survival (OS) was not reached in the entire cohort, and median event-free survival (EFS) was 42.2 months. Neither the OS nor EFS showed significant differences between the D5-PBCR (-) and D5-PBCR (+) groups. Compared to historical data, significant improvements in both OS (p = .020) and EFS (p = .020) were observed in the D5-PBCR (+) group. In conclusion, optimization of induction chemotherapy with idarubicin and cytarabine according to D5-PBCR is feasible in patients with newly diagnosed AML. The addition of HHT demonstrated a good efficacy and safety profile.

来源:Am J Hematol,查看原文。版权归原作者所有。

引用

  1. Zhang Y, Li X, Weng X, et al. Optimization of idarubicin and cytarabine induction regimen with homoharringtonine for newly diagnosed acute myeloid leukemia patients based on the peripheral blast clearance rate: A single-arm, phase 2 trial (RJ-AML 2014). Am J Hematol. 2021. PMID: 34687467. doi:10.1002/ajh.26386

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。